EY accelerates drug discovery and development in pharma

EY guides pharmaceutical companies through adopting generative AI (GenAI) to accelerate and automate early-stage drug discovery processes. GenAI enables significant breakthroughs in molecule creation, compound screening, and toxicity prediction, previously requiring extensive time and costs. EY collaborates with life sciences industry leaders, providing strategy and change management for successful GenAI implementation. The solution leverages deep learning algorithms for virtual screening, target identification, and optimal resource allocation. Predictions point toward cost savings from 44% to 67% and time reductions up to 50% for critical research phases, as GenAI adoption accelerates. The methodology streamlines clinical trial design and data analysis, improves regulatory submission, and automates documentation and compliance. EY works with both large and small biopharma companies to extend the benefits industry-wide, including for organizations lacking in-house AI capabilities. The approach helps CDMOs and CROs differentiate using advanced AI for outsourced drug research steps. Results reported by EY clients and survey respondents describe speed-to-market and cost reduction as primary impacts. The article describes a transformation in research and development operating models for faster patient benefit and broader treatment diversity.